Middle East And Africa Insulin Delivery Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.96 Billion |
| Market Size (2029) | USD 2.27 Billion |
| CAGR (2024 - 2029) | 2.99 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Middle East And Africa Insulin Delivery Devices Market Analysis
The Middle East And Africa Insulin Delivery Devices Market size is estimated at USD 1.96 billion in 2024, and is expected to reach USD 2.27 billion by 2029, growing at a CAGR of 2.99% during the forecast period (2024-2029).
An insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. Insulin infusion pumps reduce the large swings in blood glucose levels, lessen pain, and deliver more accurately than injections. The scheduling of meal timings is not required when using pumps. This makes infusion pumps more user-friendly for patients. Insulin therapy is also known as continuous subcutaneous insulin infusion (CSII). It is an efficient and flexible method of insulin delivery.
The advancement of technology has greatly enhanced the effectiveness of insulin delivery devices, resulting in improved management of glucose levels. Despite this progress, a majority of individuals who require insulin still rely on traditional methods such as syringes or traditional pens. Engaging in a conversation with your healthcare provider regarding these modern devices could greatly simplify the process of administering insulin.
In recent decades, technological advancements and innovative solutions have paved the way for a variety of insulin delivery devices, aiming to alleviate the difficulties and burdens associated with insulin administration. These devices range from simple patches to automated insulin delivery (AID) systems. However, it is noteworthy that a significant portion of insulin users still opt for the traditional combination of insulin bottles, syringes, or conventional insulin pens.
Technological advancements have increased over the period in Insulin delivery devices for safer and more accurate administration of insulin. Medtronic launched an Extended infusion set that leverages advanced materials that help reduce insulin preservative loss and maintains insulin flow and stability. The set is compatible with all MiniMed 600 and 700 series insulin pumps. The new tubing connector improves the physical and chemical stability of insulin, reliability of infusion site performance, and reduces the risk of infusion set occlusion. In addition to the new infusion set, the Medtronic Extended reservoir is also tested and approved to keep insulin stable and safely used for up to 7 days.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Middle East And Africa Insulin Delivery Devices Market Trends
The Insulin Pumps Segment is expected to witness the highest growth rate over the forecast period
The insulin pump segment is expected to register the highest growth rate of about 4.8% over the forecast period.
An insulin pump is a small battery-operated electronic device about the size of a pager or small mobile phone. The rapid-acting insulin is delivered via an infusion set that is inserted under the skin, i.e., subcutaneously. The device delivers insulin in two ways: basal (delivering small amounts of insulin continuously to maintain cell function) and bolus (delivering a dose of insulin on demand to account for the carbohydrates in meals or to correct high blood glucose levels). An insulin pump is worn 24 hours a day but can be taken off for up to two hours when required.
Data can be uploaded from insulin pumps via web-based software. The data relating to glucose concentrations and insulin delivery can be reviewed by the health professional with the patient. Randomized controlled trials have reported improvements in glycemic control using insulin pump therapy compared to multiple daily injections.
These include reductions in blood glucose, reduced hypoglycemia, lower glycated hemoglobin, lower insulin requirements, and improved quality of life. Type-1 diabetic patients need to check their blood glucose levels at regular intervals, monitor their blood glucose levels, and adjust the insulin dosing accordingly to maintain optimum glucose levels in the body.
In the Middle East and African region, in recent years, the rate of diabetes has reached an all-time high, mainly due to lifestyle changes. Governments in the Middle East have identified the threat of diabetes and started to respond with various policies, initiatives, and programs.
Six out of 15 countries in this region still do not have a national operational action policy for diabetes. Many countries still do not have a national strategy to reduce overweight, obesity, and physical inactivity, which are important risk factors for diabetes. Most counties have fully implemented national diabetes treatment guidelines. However, constant measures are being taken to minimize diabetic complications; therefore, owing to the aforesaid factors, the growth of the studied market is anticipated over the forecast period.
Iran is expected to dominate the Middle East and Africa Insulin Delivery Devices Market over the forecast period
Diabetes is a serious public health concern in Iran, the Middle East's second-largest country, due to its high prevalence rate, growing occurrence rate, and economic impact. Diabetes-related mortality in Iran continues to rise; the age-standardized death rate from diabetes has risen throughout the years. Diabetes has significant economic consequences for the country. Diabetes, in addition to its high direct healthcare costs, is a significant risk factor for other chronic illnesses, such as cardiovascular disease.
Diabetes complications accounted for USD 412 (49%) of the USD 843 per capita cost of diabetes. Yazd, a world heritage city located in the center of Iran, has one of the highest recorded prevalences of diabetes mellitus in Iran. Other cities in Iran have varying levels of diabetes awareness. For example, in Kerman, a province south of Yazd, the prevalence of undiagnosed diabetes is only 2.7%, but it is 25% in northern Iran. Despite the widespread availability of drugs and insulin coverage in Iran, the estimated national control of hyperglycemia, hyperlipidemia, and hypertension (particularly among young men and women) remains inadequate.
However, the roll-out of many new products, increasing international research collaborations in technological advancement, and increasing awareness about diabetes among people are some of the market opportunities for the players in the market.
Middle East And Africa Insulin Delivery Devices Industry Overview
The Middle East and Africa insulin delivery devices market is moderately consolidated in nature due to the presence of only a few major companies like Novo Nordisk, Sanofi, Eli Lily and Company, Medtronic, Insulet, Ypsomped, Becton Dickinson & Company, etc. operating globally and other regional players.
Middle East And Africa Insulin Delivery Devices Market Leaders
-
Becton and Dickinson
-
Medtronic PLC
-
Novo Nordisk A/S
-
Sanofi Aventis
-
Eli Lilly and Company
*Disclaimer: Major Players sorted in no particular order
Middle East And Africa Insulin Delivery Devices Market News
- January 2024: PharmaSens, a medical devices manufacturer headquartered in Switzerland, has recently filed an application with the US Food and Drug Administration (FDA) to seek approval for its innovative insulin patch pump system called 'niia essential'. This development marks a major achievement for PharmaSens in the progression of insulin pump technology.
- October 2022: Novo Nordisk announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type-2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300).
MEA Insulin Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Type
5.1.1 Insulin Pumps
5.1.1.1 Insulin Pump Device
5.1.1.2 Reservoir
5.1.1.3 Infusion Sets
5.1.2 Insulin Syringes
5.1.3 Insulin Disposable Pens
5.1.4 Insulin Cartridges in Reusable Pens
5.1.5 Jet Injectors
5.2 Geography
5.2.1 Egypt
5.2.2 Iran
5.2.3 Oman
5.2.4 Rest of Middle East and Africa
5.2.5 Saudi Arabia
5.2.6 South Africa
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk A/S
7.1.2 Sanofi
7.1.3 Eli Lilly and Company
7.1.4 Medtronic PLC
7.1.5 Insulet Corporation
7.1.6 Ypsomed
7.1.7 Becton Dickinson and Company
- *List Not Exhaustive
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk A/S
7.2.2 Sanofi
7.2.3 Eli Lilly and Company
7.2.4 Other Company Share Analyses
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Middle East And Africa Insulin Delivery Devices Industry Segmentation
There are different ways to inject insulin into a patient's body using syringes, pens, pumps, and jet injectors, giving them various options for insulin delivery. The Middle East and Africa insulin delivery devices market is segmented into type and geography. The report offers the value (in USD) and volume (in units) for the above segments.
| Type | |||||
| |||||
| Insulin Syringes | |||||
| Insulin Disposable Pens | |||||
| Insulin Cartridges in Reusable Pens | |||||
| Jet Injectors |
| Geography | |
| Egypt | |
| Iran | |
| Oman | |
| Rest of Middle East and Africa | |
| Saudi Arabia | |
| South Africa |
MEA Insulin Delivery Devices Market Research FAQs
How big is the Middle East And Africa Insulin Delivery Devices Market?
The Middle East And Africa Insulin Delivery Devices Market size is expected to reach USD 1.96 billion in 2024 and grow at a CAGR of 2.99% to reach USD 2.27 billion by 2029.
What is the current Middle East And Africa Insulin Delivery Devices Market size?
In 2024, the Middle East And Africa Insulin Delivery Devices Market size is expected to reach USD 1.96 billion.
Who are the key players in Middle East And Africa Insulin Delivery Devices Market?
Becton and Dickinson, Medtronic PLC, Novo Nordisk A/S, Sanofi Aventis and Eli Lilly and Company are the major companies operating in the Middle East And Africa Insulin Delivery Devices Market.
What years does this Middle East And Africa Insulin Delivery Devices Market cover, and what was the market size in 2023?
In 2023, the Middle East And Africa Insulin Delivery Devices Market size was estimated at USD 1.90 billion. The report covers the Middle East And Africa Insulin Delivery Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Middle East And Africa Insulin Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Middle East and Africa Insulin Delivery Devices Industry Report
Statistics for the 2024 Middle East And Africa Insulin Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Middle East And Africa Insulin Delivery Devices analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
